Pulmonary hypertension with cardiac shunt determination

6,121 views

Published on

Published in: Health & Medicine
0 Comments
8 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
6,121
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
270
Comments
0
Likes
8
Embeds 0
No embeds

No notes for slide

Pulmonary hypertension with cardiac shunt determination

  1. 1. PULMONARY HYPERTENSION AND CARDIAC SHUNT DETERMINATION DR. RAJESH DAS
  2. 2. PULMONARY HYPERTENSION OVERVIEW  Definitions  Pathogenesis  Classification  Diagnosis
  3. 3. IMPORTANT DEFINITIONS Pulmonary hypertension (PH)  is a haemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure (PAP) ≥25 mmHg at rest as assessed by right heart catheterization.  The definition of PH on exercise as a mean PAP .30 mmHg as assessed by RHC is not supported by published data and healthy individuals can reachmuch higher values. European Heart Journal (2009) 30, 2493–2537
  4. 4. HAEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION European Heart Journal (2009) 30, 2493–2537
  5. 5. PULMONARY HYPERTENSION OVERVIEW  Definitions  Pathogenesis  Classification  Diagnosis
  6. 6. THE EXACT PROCESS IS STILL UNKNOWN!! MOLECULAR ABNORMALITIES IN PAH  Prostacyclin  vasodilator,  inhibits platelet activation,  antiproliferative properties, Prostacyclin synthase is decreased in the pulmonary arteries in PAH.  Endothelin-1  Potent vasoconstrictor and stimulates PASMC proliferation. Plasma levels of ET-1 are increased in PAH and clearance is reduced.
  7. 7.  Nitric Oxide.  Vasodilator,  inhibitor of platelet activation  Inhibition of vascular smooth-muscle cell proliferation. Impaired production of NO is seen in PAH.  Serotonin (5-HT)  vasoconstrictor and promotes PASMC hypertrophy and hyperplasia. Allelic variation in serotonin transporter(SERT) present in PAH.  Vasoactive intestinal peptide (VIP)  has a pharmacologic profile similar to prostacyclins. Serum and lung tissue VIP levels are decreased in PAH patients
  8. 8. GENETICS OF PAH  Bone Morphogenetic Protein Receptor 2 Gene(BMPR2)  belong to the TGF-b superfamily involved in the control of vascular cell proliferation.  mutations are detected in at least 75% of cases PAH occurs in a familial context.  Mutations of this gene can also be detected in 25% of apparently sporadic cases.  Activin Receptor-like Kinase 1 And Endoglin  PAH associated with HHT.
  9. 9. PATHOGENESIS OF PAH Gaine S. J Am Med Assoc 2000;284:3160-68
  10. 10. PULMONARY HYPERTENSION OVERVIEW  Definitions  Pathogenesis  Classification  Diagnosis
  11. 11. CLASSIFICATION OF PULMONARY HYPERTENSION  First attempt in 1973 meeting organized by the WHO.  A distinction was made between primary and secondary PH  The Dana Point 2008 4th World Symposium on PH  Based on shared pathologic, pathobiologic, and clinical features.
  12. 12. UPDATED CLINICAL CLASSIFICATION OF PULMONARY ARTERIAL HYPERTENSION (DANA POINT, 2008) 1 Pulmonary arterial hypertension (PAH) 1.1 Idiopathic 1.2 Heritable  1.2.1 BMPR2  1.2.2 ALK1, endoglin (with or without hereditary haemorrhagic telangiectasia)  1.2.3 Unknown 1.3 Drugs and toxins induced 1.4 Associated with (APAH)  1.4.1 Connective tissue diseases  1.4.2 HIV infection  1.4.3 Portal hypertension  1.4.4 Congenital heart disease  1.4.5 Schistosomiasis  1.4.6 Chronic haemolytic anaemia 1.5 Persistent pulmonary hypertension of the newborn 1’ Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis J Am Coll Cardiol 2009;54:S43–S54.
  13. 13. UPDATED CLINICAL CLASSIFICATION OF PULMONARY ARTERIAL HYPERTENSION (DANA POINT, 2008) 2. Pulmonary hypertension due to left heart disease 2.1. Systolic dysfunction 2.2. Diastolic dysfunction 2.3. Valvular disease 3. Pulmonary hypertension due to lung diseases and/or hypoxia 3.1. Chronic obstructive pulmonary disease 3.2. Interstitial lung disease 3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 3.4. Sleep-disordered breathing 3.5. Alveolar hypoventilation disorders 3.6. Chronic exposure to high altitude 3.7. Developmental abnormalities
  14. 14. UPDATED CLINICAL CLASSIFICATION OF PULMONARY ARTERIAL HYPERTENSION (DANA POINT, 2008) 4. Chronic thromboembolic pulmonary hypertension (CTEPH) 5. PH with unclear multifactorial mechanisms 5.1. Hematologic disorders: myeloproliferative disorders splenectomy. 5.2. Systemic disorders, sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vas culitis 5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
  15. 15. EPEDIOMOLOGY  Commonest cause of PH in adults is COPD.  Estimated incidence of IPAH is 1-2 newly diagnosed cases per million people per year.  Prevalence of PAH in adult CHD- 5–10%, out of which 25- 50% presenting with ES. Rev Esp Cardiol. 2010 Oct;63(10):1179-93
  16. 16. PH WITH CARDIAC SHUNT  PAH associated with CHD is included in group 1 of the PH clinical classification.  Persistent exposure of the pulmonary vasculature to increased blood flow may result in a typical pulmonary obstructive arteriopathy (identical to other PAH forms) that leads to the increase of PVR. Rev Esp Cardiol. 2010 Oct;63(10):1179-93
  17. 17. CLINICAL CLASSIFICATION OF CONGENITAL SYSTEMIC-TO- PULMONARY SHUNTS ASSOCIATED WITH PAH A. Eisenmenger’s syndrome  ES includes all systemic-to-pulmonary shunts due to large defects leading to a severe increase in PVR and resulting in a reversed or bidirectional shunt.  Cyanosis, erythrocytosis, and multiple organ involvement are present. B. PAH associated with systemic-to-pulmonary shunts  In these patients with moderate to large defects, the increase in PVR is mild to moderate, systemic-to-pulmonary shunt is still largely present.  no cyanosis is present at rest. European Heart Journal (2009) 30, 2493–2537
  18. 18. C. PAH with small defects  usually VSD<1 cm and ASD<2 cm of effective diameter assessed by echocardiography.  clinical picture similar to idiopathic PAH. D. PAH after corrective cardiac surgery  PAH is either still present immediately after surgery or has recurred several months or years after surgery in the absence of significant post-operative residual congenital lesions. European Heart Journal (2009) 30, 2493–2537 CLINICAL CLASSIFICATION OF CONGENITAL SYSTEMIC-TO- PULMONARY SHUNTS ASSOCIATED WITH PAH
  19. 19. PULMONARY HYPERTENSION OVERVIEW  Definitions  Pathogenesis  Classification  Diagnosis
  20. 20. WHEN SHOULD THE DIAGNOSIS OF PAH BE CONSIDERED?  Patients with unexplained exercise limitation  Patients with clinical signs consistent with right heart dysfunction  Patients with abnormal right ventricular findings on radiography, echocardiography or electrocardiography  Patients with systemic disease known to be associated with PAH
  21. 21. SYMPTOMS ASSOCIATED WITH PAH  Shortness of breath  Syncope  Chest pain  Symptoms of RH dysfunction Breathlessness Ascites Ankle swelling Anorexia
  22. 22. SIGNS ASSOCIATED WITH PAH  Loud split P2  RV hypertrophy  Increased “a” waves  Increased “v” waves  Diastolic murmur (PR)  Pansystolic murmur (TR)
  23. 23. SIGNS OF RH FAILURE  Poor peripheral perfusion  Raised RA pressure  RV 3rd and 4th heart sounds  Tricuspid regurgitation  Ejection systolic murmur across the pulmonary valve
  24. 24. WHO CLASSIFICATION OF FUNCTIONAL STATUS OF PATIENTS WITH PH
  25. 25. DIAGNOSIS OF PH WITH CARDIAC SHUNTS  The signs and symptoms of Eisenmenger’s syndrome result from PH, low arterial O2 saturation, and secondary erythrocytosis.  They include dyspnoea, fatigue, and syncope.  haemoptysis, cerebrovascular accidents, brain abscesses, coagulation abnormalities, and sudden death.
  26. 26. PULMONARY ARTERIAL HYPERTENSION: CLINICAL COURSE AND PROGRESSION CLEVELAND CLINIC JOURNAL OF MEDICINE 2007. 74(10)
  27. 27. DIAGNOSTIC ALGORITHM FOR PAH European Heart Journal (2009) 30, 2493–2537 Contd on next slide
  28. 28. DIAGNOSTIC ALGORITHM FOR PAH CONTD.. European Heart Journal (2009) 30, 2493–2537
  29. 29. FINDINGS ON ELECTROCARDIOGRAM • Highly specific but not very sensitive. • RVH, RAE, RAD, RBBB.
  30. 30. FINDINGS IN PH CHEST RADIOGRAPHY  Cardiac enlargement  Prominent proximal PA  “Pruning” of distal PA
  31. 31. ECHOCARDIOGRAPHY IN PAH  T R  RVE  RAE  RVH  Flattening of IVS  Dilated IVC
  32. 32. VENTILATION PERFUSION LUNG SCAN IPAH CTEPH
  33. 33. CT FEATURES OF PULMONARY HYPERTENSION  Wall-adherent thrombotic material in pulmonary arteries  CTEPH  Severe idiopathic pulmonary arterial hypertension  Calcifications in pulmonary arteries  CTEPH  Longstanding severe pulmonary hypertension  Eisenmenger syndrome  Peripheral pulmonary arteriovenous shunting  Portopulmonary hypertension  Hepatopulmonary syndrome  Pulmonary vascular dilatation (central or peripheral)  Left-to-right shunt RadioGraphics 2010; 30:1753–1777
  34. 34. MAGNETIC RESONANCE IMAGING (MRI)  Useful for Assessment of congenital heart diseases in children and adults:  visceral-atrial situs,  connection and course of great veins and arteries,  Hidden septal defects (sinus venosus ASD and supracristal, or posterior ventricular septal defects)  above all, assessment of the size and function of the cardiac chambers, and in particular the right ventricle Rev Esp Cardiol. 2007;60(9):895-8
  35. 35. GENETIC TESTING Genetic testing and professional genetic counseling should be offered to relatives of patients with FPAH. CHEST 2007; 131:1917–1928
  36. 36. 6 MINUTE WALK TESTING In patients with PAH, serial determinations of functional class and exercise capacity assessed by the 6 minute walk test provide benchmarks for disease severity, response to therapy, and progression. CHEST 2007; 131:1917–1928
  37. 37. TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE)  Useful in detection of intracardiac shunts, especially ASD and detect central pulmonary emboli CHEST 2007; 131:1917–1928
  38. 38. PULMONARY ANGIOGRAPHY  In patients with PAH and a V/Q scan suggestive of CTEPH, pulmonary angiogram is required for accurate diagnosis and best anatomic definition to assess operability. CHEST 2007; 131:1917–1928
  39. 39. RIGHT HEART CATHETERIZATION  -CONFIRMATION OF DIAGNOSIS  -EXCLUSION OF OTHER CAUSES  -ESTABLISH SEVERITY  -ASSEMENT OF PROGNOSIS  -ASSESMENT OF PULMONARY VASOREACTIVITY:  challenge with inhaled NO, intravenous epoprostenol or intravenous adenosine.  Positive Response:  >10mm mean PAP decrease and  < 30mmHg final mean PAP  > 33% decrease in PVR, ideally to < 6 units.  Unchanged or increased CI CHEST 2007; 131:1917–1928
  40. 40. PROGNOSIS
  41. 41. NATURAL HISTORY AND SURVIVAL
  42. 42. INTRACARDIAC SHUNT ESTIMATION
  43. 43. INTRACARDIAC SHUNTS Left-to-right shunt Right-to-left shunt Bidirectional shunt
  44. 44. WHEN TO SUSPECT DURING CATHETERIZATION?  unexplained pulmonary artery oxygen saturation exceeding 80%(? Left-Right shunt)  unexplained arterial desaturation <95% (Right- left shunt)  Arterial desaturation commonly results from alveolar hypoventilation and associated physiological shunting  oversedation from premedication,  pulmonary disease,  pulmonary venous congestion,  pulmonary edema,  cardiogenic shock.
  45. 45. METHODS TO ESTIMATE SHUNTS Cardiac Catheterisation  Oximeric method  Indicator dilution method Echocardiography
  46. 46. PRINCIPLES OF THE OXYMETRIC METHOD  Blood Sampling from various chambers to determine Oxygen Saturation.  Left to Right Shunt is present when a significant increase in blood oxygen saturation is found between 2 right sided vessels or chambers.
  47. 47. OXIMETRIC METHOD  A “screening” oxygen saturation measurement is done by sampling of blood in the SVC and the pulmonary artery.  If the difference is 8% or more, a left-to-right shunt may be present, and an oximetry “run” is performed.
  48. 48. OXIMETRIC RUN Obtain a 2-ml sample from each of the following locations: 1. Left and or right PA. 2. Main PA. 3. RVOT. 4. RV-mid 5. RV-tricuspid valve or apex 6. RA- low or near tricuspid valve 7. RA- mid 8.RA- high 9. SVC- low (near junction with right atrium) 10. SVC- high (near junction with innominate vein) 11. IVC- high (just at or below diaphragm) 12. IVC- low L4-L5) 13. LV 14. Aorta(distal to insertion of ductus )
  49. 49. OXIMETRIC RUN For localizing Right to Left Shunts one should also obtain samples from….  Pulmonary Vein  Left Atrium  Left Ventricle  Distal Aorta
  50. 50. OXIMETRY RUN  A significant step-up is defined as an increase in blood oxygen content or saturation that exceeds the normal variability that might be observed if multiple samples were drawn from that cardiac chamber.  O2 content (ml/L)= SpO2 × 1.36 (ml/g) × Hb (g/dL) × 10  1 vol% = 1ml O2/100ml blood or 10 ml O2/L
  51. 51. OXIMETRY RUN Dexter Criteria: significant step-up in oximetry run :  Right Atrium: Highest O2 content in blood samples drawn from the RA exceeds the highest content in the venae cavae by 2 vol % .  Right ventricle: If the highest RV sample is 1 vol % higher than the highest RA sample.  Pulm. artery: the PA oxygen content is more than 0.5 vol% greater than the highest RV sample.
  52. 52. OXIMETRY RUN  a Difference distal- proximal chamber.
  53. 53. QUANTIFICATION OF SHUNT
  54. 54. FICK EQUATION  The principles used to determine Fick cardiac output are also used to quantify intra-cardiac shunts.  Flow= Oxygen consumption/Arterial- Venous oxygen content difference.  O2 consumption is assumed based on patient’s age, gender and body surface area when not directly measured.
  55. 55. CALCULATION OF PULMONARY BLOOD FLOW (QP)
  56. 56. CALCULATION OF SYSTEMIC BLOOD FLOW (QS)
  57. 57. WHAT IS MIXED VENOUS O2 CONTENT?  The MVO2 (mixed venous oxygen content) is the average oxygen content of the blood in the chamber proximal to the shunt.  When assessing a left-to-right shunt at the level of the RA, mixed venous oxygen content is calculated by the Flamm formula:  MVO2 = 3(SVC O2 content) + (IVC O2 content) 4
  58. 58. CALCULATION OF BIDIRECTIONAL SHUNTS  Effective blood flow: the flow that would exist in the absence of any left-to-right or right-to-left shunting:
  59. 59.  L → R shunt = PBF – SBF (Or Qp – Qs) Bidirectional shunts:  L → R shunt = PBF – EBF (or Qp – QEP)  R → L shunt = SBF – EBF (or Qs – QEP) SHUNT CALCULATION
  60. 60. CLINICAL SIGNIFICANCE OF SHUNT 
  61. 61. INDICATOR DILUTION METHOD  More sensitive than the oximetric method in detection of small shunts.  Cannot be used to localize the level of a left-to-right shunt.  Dye used- Indocyanine Green.  Left to Right : Dye is injected into pulmonary artery and a sample is taken from the systemic artery.  Right to Left: dye injected just proximal to the presumed shunt and blood sample is taken from systemic artery
  62. 62. SHUNT ESTIMATION BY ECHOCARDIOGRAPHY  PW Doppler or color flow imaging:  flow disturbance is found downstream from the defect.  velocity of blood flow through the shunt orifice is related to the pressure gradient  2D imaging;  ASD-Dilation RA and RV,paradoxical septal motion .  PDA & VSD: Dilation LA and LV.
  63. 63. IMPORTANCE OF PULMONARY VASCULAR RESISTANCE CONGENITAL CENTRAL SHUNTS  The decision as to whether a patient with congenital heart disease would profit from corrective surgery often hinges on the calculated pulmonary vascular resistance.  IMPORTANT CALCULATIONS:  PVR  PVR:SVR ratio.
  64. 64. PULMONARY VASCULAR RESISTANCE  PVR = mean PAP – mean LAP (or PCWP) Qp -in Woods Unit (mmHg/L/min)  SVR = mean systemic arterial P – mean RAP Qs  PVRI= PVR/ BSA (Sq. m.)
  65. 65. FAVOURABLE OUTCOME IN SURGERY  A baseline PVRI <6 Woods units/m2 associated with a resistance ratio of <0.3 without a vasoreactivity test is interpreted as indicative of a favorable outcome following operations resulting in a biventricular circulation.
  66. 66. FAVORABLE OUTCOME IN SURGERY Acute vasodilator challenge using oxygen/ nitric oxide:  Done if baseline PVRI is between 6 and 9 Wood units/m2 in the presence of a resistance ratio from around 0.3-0.5.  favorable outcome:  A decrease of 20% in the PVRI.  A decrease of around 20% in the ratio of pulmonary to systemic vascular resistance  A final PVR index of <6 Woods units/m2.  A final ratio of resistance of <0.3.
  67. 67. THANK YOU……

×